Smoking Status To Predict Sensitivity To Parp Inhibitor, Veliparib, In Patients With Advanced Nsclc.

8038 Background: Tobacco-related non-small cell lung cancer (NSCLC) is associated with reduced survival and greater genomic instability. Veliparib (V) is a PARP inhibitor that augments platinum-induced DNA damage in preclinical studies, and a recent Ph 2 trial of advanced NSCLC trended to improved survival (HR 0.80; CI 0.54–1.18) when V was added to carboplatin (C) and paclitaxel (P). Here we report outcomes based on smoking status from a randomized Ph 2 study of CP with either V or placebo in advanced NSCLC. Methods: Patients (pts) with previously untreated advanced/metastatic NSCLC were randomized 2:1 to CP with either V at 120 mg BID or placebo (pre-specified stratification by histology and smoking history). Cotinine (COT) was measured in pt plasma samples as an index of recent tobacco use. Results: Of 158 pts, 68% were male, and 49% had squamous NSCLC. At study entry, 60% of pts were self-reported current smokers (CS), 27% former smokers, and 13% never smoked. There were no significant differences in ...